Jacob Ellery Corn

Jacob Ellery Corn

Auto-generated profile, based on publicly available information

Jacob Ellery Corn

Institute of Molecular Health Sciences, Department of Biology, ETH Zurich, Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011
Verified
Book Chapter
Closed access
ALAndrew Leaver-Fay
Andrew Leaver-Fay
MTMichael Tyka
Michael Tyka
SLSteven M. Lewis
Steven M. Lewis
OLOliver F. Lange
Oliver F. Lange
JTJames Thompson
James Thompson
PBPhilip Bradley
Philip Bradley

20 January 2016 in Nature Biotechnology
Verified
Journal Article
Closed access
CRChristopher D Richardson
Christopher D Richardson
GRGraham J Ray
Graham J Ray
MDMark A DeWitt
Mark A DeWitt
GCGemma L Curie
Gemma L Curie
JCJacob E Corn
Jacob E Corn

23 September 2016 in eLife
Verified
Journal Article
Open access
MHMax A Horlbeck
Max A Horlbeck
LGLuke A Gilbert
Luke A Gilbert
JVJacqueline E Villalta
Jacqueline E Villalta
BABritt Adamson
Britt Adamson
RPRyan A Pak
Ryan A Pak
JWJonathan S Weissman
Jonathan S Weissman
We recently found that nucleosomes directly block access of CRISPR/Cas9 to DNA (Horlbeck et al., 2016). Here, we build on this observation with a comprehensive algorithm that incorporates chromatin, position, and sequence features to accurately predict highly effective single guide RNAs (sgRNAs) for targeting nuclease-dead Cas9-mediated transcriptional repression (CRISPRi) and activation (CRISPRa). We use this algorithm to design next-generation genome-scale CRISPRi and CRISPRa libraries targeting human and mouse genomes. A CRISPRi screen for essential genes in K562 cells demonstrates that the large majority of sgRNAs are highly active. We also find CRISPRi does not exhibit any detectable non-specific toxicity recently observed with CRISPR nuclease approaches. Precision-recall analysis shows that we detect over 90% of essential genes with minimal false positives using a compact 5 sgRNA/gene library. Our results establish CRISPRi and CRISPRa as premier tools for loss- or gain-of-function studies and provide a general strategy for identifying Cas9 target sites.

24 June 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SFSarel Fleishman
Sarel Fleishman
ALAndrew Leaver-Fay
Andrew Leaver-Fay
JCJacob E. Corn
Jacob E. Corn
ESEva-Maria Strauch
Eva-Maria Strauch
SKSagar D. Khare
Sagar D. Khare
DBDavid Baker
David Baker
Macromolecular modeling and design are increasingly useful in basic research, biotechnology, and teaching. However, the absence of a user-friendly modeling framework that provides access to a wide range of modeling capabilities is hampering the wider adoption of computational methods by non-experts. RosettaScripts is an XML-like language for specifying modeling tasks in the Rosetta framework. RosettaScripts provides access to protocol-level functionalities, such as rigid-body docking and sequence redesign, and allows fast testing and deployment of complex protocols without need for modifying or recompiling the underlying C++ code. We illustrate these capabilities with RosettaScripts protocols for the stabilization of proteins, the generation of computationally constrained libraries for experimental selection of higher-affinity binding proteins, loop remodeling, small-molecule ligand docking, design of ligand-binding proteins, and specificity redesign in DNA-binding proteins.

2 October 2017 in Nature Biomedical Engineering
Verified
Journal Article
Open access
PDF file
KLKunwoo Lee
Kunwoo Lee
MCMichael Conboy
Michael Conboy
HPHyo Min Park
Hyo Min Park
FJFuguo Jiang
Fuguo Jiang
HKHyun Jin Kim
Hyun Jin Kim
Niren MurthyNiren Murthy
Niren Murthy
Clustered regularly interspaced short palindromic repeats (CRISPR)–CRISPR associated protein 9 (Cas9)-based therapeutics, especially those that can correct gene mutations via homology-directed repair, have the potential to revolutionize the treatment of genetic diseases. However, it is challenging to develop homology-directed repair-based therapeutics because they require the simultaneous in vivo delivery of Cas9 protein, guide RNA and donor DNA. Here, we demonstrate that a delivery vehicle composed of gold nanoparticles conjugated to DNA and complexed with cationic endosomal disruptive polymers can deliver Cas9 ribonucleoprotein and donor DNA into a wide variety of cell types and efficiently correct the DNA mutation that causes Duchenne muscular dystrophy in mice via local injection, with minimal off-target DNA damage.

25 September 2017 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MMMaxwell R Mumbach
Maxwell R Mumbach
ASAnsuman T Satpathy
Ansuman T Satpathy
EBEvan A Boyle
Evan A Boyle
CDChao Dai
Chao Dai
BGBenjamin G Gowen
Benjamin G Gowen
HCHoward Y Chang
Howard Y Chang